Endo Health Solutions ENDP today announced that its Qualitest
subsidiary has reached a definitive agreement to acquire privately held Boca
Pharmacal, a specialty generics company, for $225 million in cash. The
transaction is expected to enhance the growth platform and pipeline for Endo's
Qualitest business and is consistent with Endo's strategic transformation into
a leading specialty healthcare company.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in